José Lopes, PhD, managing science editor —

José holds a PhD in neuroscience from the University of Porto, Portugal. After postdocs at Weill Connell Medicine and Western University, where he studied the processes driving hypertension and Alzheimer’s disease, he moved on in 2016 to a career in science writing and communication. José is the author of several peer-reviewed papers and a book chapter and has presented his research in numerous international meetings.

Articles by José Lopes

Cannabinoids May Improve Muscle Function in Myasthenia Gravis, Mouse Study Suggests

Treatment with cannabinoids improved muscle function in a mouse model of myasthenia gravis (MG), suggesting they may have therapeutic potential for the disease, researchers say. The study, “Cannabinoid-induced increase of quantal size and enhanced neuromuscular transmission,” appeared in the journal Scientific Reports. Cannabinoids regulate multiple levels of neuronal communication,…

MG Patient Successfully Treated with Weekly Blood Purification Therapy, Case Report Says

Japanese researchers wrote about a myasthenia gravis (MG) patient who showed long-term improvement in disease symptoms after he was treated with blood purification therapy. The case report, “A Case of Anti-MuSK Antibody-positive Myasthenia Gravis Successfully Treated With Outpatient Periodic Weekly Blood Purification Therapy,” appeared in Internal Medicine, the journal…

Scabies Skin Infestation Increases Risk of MG, Taiwanese Study Finds

Scabies infection boosts one’s risk of developing myasthenia gravis (MG), new research from Taiwan shows. The study, “The association between scabies and myasthenia gravis: A nationwide population-based cohort study,” appeared in the Journal of Clinical Neuroscience. Scabies is an infectious, highly contagious skin disease caused by the mite…

Soliris Keeps Improving Myasthenia Gravis Symptoms During Extension of Phase 3 Trial

Soliris (eculizumab) continued improving myasthenia gravis patients’ muscle strength and functioning in a 52-week extension of a 26-week Phase 3 clinical trial, researchers reported. Alexion Pharmaceuticals said the extension study covered the same category of participant: patients with refractory generalized myasthenia gravis (gMG) who have anti-acetylcholine receptor (AchR) antibodies. The original Phase 3 trial…